FRANKFURT (Reuters) – Drugmakers on Monday pledged to speed up the market launch of new drugs in underserved EU member states in a bid to avert stricter regulation by Brussels. European Federation of Pharmaceutical Industries and Associations (EFPIA) said in a statement on Monday its members pledge to file for reimbursement by national health systems no later than two years after EU regulatory approval, “provided that local systems allow it”. While EU drug approval is largely centralised, with the European Medicines Agency acting as watchdog, procedures to subsequently set the treatment price …